IFNAR2 Antibody

Code CSB-PA011047GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
IFNAR2
Alternative Names
Human interferon alpha/beta receptor antibody; IFN alpha REC antibody; IFN R antibody; IFN-alpha binding protein antibody; IFN-alpha/beta receptor 2 antibody; IFN-R-2 antibody; IFNABR antibody; IFNAR2 antibody; IFNARB antibody; IFNR antibody; INAR2_HUMAN antibody; Interferon (alpha beta and omega) receptor 2 antibody; Interferon alpha binding protein antibody; Interferon alpha/beta receptor 2 antibody; Interferon alpha/beta receptor beta chain antibody; Type I interferon receptor 2 antibody; Type I interferon receptor antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Human IFNAR2
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Associates with IFNAR1 to form the plasma membrane receptor in the type I interferon signaling pathway. Directly involved in signal transduction through its association with the TYR kinase JAK1. Involved in interferon-mediated STAT1, STAT2 and STAT3 activation.; Potent inhibitor of type I IFN receptor activity.
Gene References into Functions
  1. The findings underline the roles of UL36USP-IFNAR2 interaction in counteracting the type I IFN-mediated signaling pathway and reveal a novel evasion mechanism of antiviral innate immunity by HSV-1. PMID: 29997210
  2. Report lowered serum IFNAR2 levels in multiple sclerosis patients are elevated on treatment with interferon-beta. PMID: 27613121
  3. this study shows that the surface expression levels of the common IFN-alpha/beta receptor subunit 2 are significantly higher on plasmacytoid dendritic cells from females in comparison to males PMID: 27891600
  4. A very small percentage of the pancreatic tumors showed strong expression of the IFNAR-2c. PMID: 25072284
  5. Lack of expression of functional IFNAR2 does not seem to be the major cause of interferon resistance in hepatitis C virus patients receiving standard interferon therapy. PMID: 26176069
  6. The effects of two functional polymorphisms, type I interferon receptor 2 gene (IFNAR2)-F8S and interleukin-10 receptor subunit beta gene (IL10RB)-K47E, on chronic hepatitis B virus (HBV) infection, were investigated. PMID: 23745570
  7. IFNAR2 overexpression was observed in various histological types of lung cancer, and appears to be associated with lung cancers that behave aggressively. PMID: 22236545
  8. In this study we have characterized the Stat2-IFNaR2 interaction and examined its role in IFNalpha signaling PMID: 11786546
  9. STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c PMID: 12105218
  10. Expression and signaling activity of interferon alpha/beta receptors modulates dendritic cell (DC) responsiveness during terminal maturation and differentiation of monocyte-derived DCs. PMID: 12218119
  11. Subunit 2 of the interferon alpha receptor (IFNaR2) is bound more avidly to Stat2 than is phosphorylated IFNaR1. PMID: 12220192
  12. Administration as a complex with sIFNAR-2 may provide a method of enhancing the delivery and effectiveness of type I interferons in Burkitt lymphoma in scid mice. PMID: 14980076
  13. IFNaR2, a subunit of the type I IFN receptor, is proteolytically cleaved in a regulated manner. PMID: 15286706
  14. Dynamics of the IFNAR2 extracellular domain binding site reveal highly flexible loop segments and a malleable binding surface interacting with the IFN ligand supported by a more rigid scaffold which stabilizes the binding site conformation. PMID: 15287740
  15. A dynamic model for the IFN-alpha/receptor complex predicts that IFNAR2 and IFNAR1 are probably anchored in close proximity on the cell surface and that upon IFN binding, the complex assumes a closed form, resulting in activation of intracellular kinases. PMID: 15449939
  16. IFNaR2 intracellular domain transcriptional modulation is dependent upon the carboxyl-terminal transactivation domain of Stat2. PMID: 15717316
  17. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. PMID: 16054712
  18. Oveexpression of IFNAR2 is associated with hepatocellular carcinoma PMID: 16106266
  19. Hepatic IFNAR2c mRNA expression appears to correlate inversely with the fibrosis stage and age in hepatitis C infection. PMID: 16518956
  20. Monocyte-derived dendritic cells can modulate their sensitivity to two IFN subtypes by differential regulation of the IFNAR subunits. PMID: 16624932
  21. IFNAR2 cytoplasmic domain serves to link STAT4 to the IFNAR as a pre-assembled complex that facilitates cytokine-driven STAT4 activation. PMID: 17095088
  22. binding of IFN-alpha8 rather than binding of IFN-alpha2 to IFNAR-2 leads to activation and subsequent antiproliferative activity despite the same antiviral activity in renal cell carcinoma PMID: 17572016
  23. The intensity and distribution of IFNAR-2 may predict the response to therapy with IFN-alpha and IFN-beta in pancreatic cancer. PMID: 17667505
  24. High IFNAR2 is associated with renal cell carcinoma metastasis PMID: 17697365
  25. Results demonstrated that FNAR2-extracellular domain interact differentially with two individual IFN-alphas, suggesting the mutual interaction between multiple IFN-alpha subtypes during the competition for binding to the receptor. PMID: 18027911
  26. The data suggest that liberation of the IFNaR2-ICD by regulated proteolysis could trigger a novel mechanism for moving the transcription factor Stat2 to the nucleus. PMID: 18456457
  27. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor PMID: 18456658
  28. Findings show that interferon-alpha/beta receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFNbeta). PMID: 18971450
  29. Results suggest that zinc, especially polaprezinc, enhances the expression of type 1 interferon 2 receptor in U937 cells, thereby inducing production of the anti-viral protein 2'-5'OAS. PMID: 19362011
  30. Ep-CAM is a potentially useful marker for resistance to INFalpha/5-FU therapy, especially in IFNAR2-positive cases. PMID: 19401692
  31. The IFNAR2-8SS genotype was associated with HBeAg negative patients; IFNAR2-8F allele was associated with the risk to high viral loads; the IFNAR2-8FF genotype predisposed to higher MxA gene induction and correlated with sustained IFN response. PMID: 19714778

Show More

Hide All

Involvement in disease
Immunodeficiency 45 (IMD45)
Subcellular Location
[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Secreted.
Protein Families
Type II cytokine receptor family
Tissue Specificity
Isoform 3 is detected in the urine (at protein level). Expressed in blood cells. Expressed in lymphoblastoid and fibrosarcoma cell lines.
Database Links

HGNC: 5433

OMIM: 602376

KEGG: hsa:3455

STRING: 9606.ENSP00000343957

UniGene: Hs.708195

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*